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Antibiotics in early life associate with specific gut microbiota
signatures in a prospective longitudinal infant cohort
Katri Korpela1, Anne Salonen1, Harri Saxen2, Anne Nikkonen2, Ville Peltola3, Tytti Jaakkola2, Willem de Vos1,4 and Kaija-Leena Kolho1,2,5,6
BACKGROUND: The effects of antibiotics on infant gut microbiota are unclear. We hypothesized that the use of common
antibiotics results in long-term aberration in gut microbiota.
METHODS: Antibiotic-naive infants were prospectively recruited when hospitalized because of a respiratory syncytial virus
infection. Composition of fecal microbiota was compared between those receiving antibiotics during follow-up (prescribed at
clinicians’ discretion because of complications such as otitis media) and those with no antibiotic exposure. Fecal sampling started
on day 1, then continued at 2-day intervals during the hospital stay, and at 1, 3 and 6 months at home.
RESULTS: One hundred and sixty-three fecal samples from 40 patients (median age 2.3 months at baseline; 22 exposed to
antibiotics) were available for microbiota analyses. A single course of amoxicillin or macrolide resulted in aberration of infant
microbiota characterized by variation in the abundance of bifidobacteria, enterobacteria and clostridia, lasting for several months.
Recovery from the antibiotics was associated with an increase in clostridia. Occasionally, antibiotic use resulted in microbiota
profiles associated with inflammatory conditions.
CONCLUSIONS: Antibiotic use in infants modifies especially bifidobacterial levels. Further studies are warranted whether
administration of bifidobacteria will provide health benefits by normalizing the microbiota in infants receiving antibiotics.
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INTRODUCTION
The healthy infant gut microbiota develops in the first years of life
according to an apparently biologically determined schedule, yet
is depending strongly on external exposures.1 The microbiota is
initially dominated by facultative anaerobic taxa, such as
streptococci, enterococci, and enterobacteria. During the first
weeks of life, the abundance of bifidobacteria increases and
become the dominant taxon in breastfed infants.1 Antibiotics have
been identified as exerting a strong influence on the infant gut
microbiota, with a particularly negative impact on bifidobac-
teria.2,3 In infancy, the gut microbiota is thought to guide the
development of the immune system, via direct contact with host
cells at the gut mucosal interface.4 Owing to their high abundance
at this age period, bifidobacteria very likely have an important role
in overall infant development, and there is reason to believe that
the antibiotic-associated disruption of gut microbiota in infants
may have long-term health consequences.
Antibiotic use during the first year of life has been linked with
increased risk of, e.g., cow’s milk allergy,5 asthma, eczema, hay
fever, wheeze, atopy,6 and inflammatory bowel disease.7,8 Experi-
mental mice studies have shown that antibiotic exposure in early
life alters the development of the immune system.9 Furthermore,
studies in neonatal mice implicate changes in the gut microbiota
as the causal link between antibiotics and altered immune system
development.10 Indeed, an association between the gut microbiota
composition during the first months of life and later development
of allergic disease has been shown repeatedly in humans.11
In addition to the immunological effects, the early-life gut
microbiota is emerging as an important factor regulating the
overall physiology of the host, especially metabolism.12 Low
abundance of bifidobacteria during the first months of life has
been found to be associated with increased body mass index in
later childhood.13 Animal studies showed that metabolites of the
gut microbes influence epigenetic programming,14 and early-life
transient disruption of the gut microbiota by antibiotic treatment
has revealed long-lasting detrimental metabolic consequences on
the host, increasing the susceptibility to diet-induced obesity.15
Several epidemiologic studies have shown an association between
early-life antibiotic exposure and the risk of overweight in later
life.16,17 Intervention studies in low-income countries have
indicated that antibiotics have a growth-promoting effect in
children.18,19
The accumulating evidence of the long-term adverse effects
caused by early-life antibiotic treatment increasingly underscores
the importance of finding ways to mitigate the effects. The impact
of antibiotic use on the development of antibiotic resistance can
be reduced by limiting the duration of the antibiotic course,20 and
the same approach could hypothetically alleviate the impact on
the gut microbiota. However, the temporal dynamics of the gut
microbiota during and after antibiotic treatments in infants are
currently not clearly understood. We address this question in a
cohort of 40 infants by analyzing the development of the gut
microbiota before, during, and after amoxicillin and macrolide
treatments and comparing these to control infants with no
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antibiotic treatments. We posed the research question: Does the
use of common antibiotics result in long-term aberration in the
gut microbiota of infants?. Accordingly, we hypothesized that the
use of common antibiotics results in long-term aberration in gut
microbiota.
METHODS
Subjects and fecal sample collection
All participants were prospectively recruited on the first day of
their hospitalization because of a respiratory syncytial virus (RSV)
infection at Children’s Hospital, University of Helsinki, and Turku
University Hospital between December 2013 and May 2014. We
only included infants who were antibiotic naive at recruitment
according to parental report. Fecal sampling started on admission
and was thereafter instructed as follows: on day 1 and thereafter
at 2-day intervals during hospital stay and at 1, 3, and 6 months at
home. Samples were immediately frozen at −20 °C and trans-
ported frozen at −70 °C until analyzed. At the time of each
sampling, the families filled out a questionnaire on diet, probiotics
used, and previous antibiotic therapies as appropriate. Details of
birth mode, disease and outcomes, growth, and weight gain were
checked on patient files. Of the 58 recruited patients, there were
163 fecal samples from 40 patients available for microbiota
analyses (median 4.5, range 1–9 samples per patient). Of these, 14
infants received antibiotics during admission for RSV infection and
other 8 during follow-up (Supplementary Fig. S1 and Supplemen-
tary Table S1), mostly because of otitis media. The latter eight
samples were accordingly instructed to be collected at home.
Preterm infants (birth <37 gestational week or birth weight <2500
g) or those with congenital malformations or syndromes were
excluded. None of the infants had been traveling abroad.
Background data of the study participants are presented in
Supplementary Table S1.
Sample processing and sequencing
Bacterial DNA was extracted from ca. 125mg of fecal samples
using repeated bead-beating method21 with the following
modifications for automated DNA purification: After the bead-
beating steps, 400 μl of the pooled cell lysates was purified with
the RSC Blood DNA Kit AS1400 using Promega Maxwell RCS
instrument (Promega, Madison, WI). DNA was quantified using
Quanti-iT™ Pico Green dsDNA Assay (Invitrogen, San Diego, CA).
Library preparation and sequencing
Illumina MiSeq paired-end sequencing of the hypervariable V3–V4
regions of the 16S rRNA gene was performed at the sequencing
unit of Institute for Molecular Medicine Finland, Helsinki, Finland.
The protocol followed that from Illumina except that the libraries
were prepared with single-step polymerase chain reaction (PCR),
i.e., by combining amplicon and index PCR in the same reaction,
and index primers were adapted from Kotzich et al.22 The PCR
reaction comprised of 1 ng/μl template, 1× Phusion® Master Mix
(ThermoFisher, F-531L), 0.25 μM V3–V4 16S rRNA gene primers,
and 0.375 μM dual-index primers. The PCR was run under the
following settings: 98 °C for 30 s, 27 cycles of 98 °C for 10 s, 62 °C
for 30 s, 72 °C for 15 s, and finally 10 min at 72 °C, whereafter the
samples were stored at 4 °C. The amplicon size (ca. 640 bp) was
verified on LabChip GX Touch HT instrument (PerkinElmer,
Waltham, MA). The PCR clean-up was performed with AMPure
XP beads (Beckman Coulter, Copenhagen, Denmark) and con-
firmation of the right size of the target was performed on a
Bioanalyzer DNA 1000 chip (Agilent Technology, Santa Clara, CA).
The pooled libraries were sequenced with an Illumina MiSeq
instrument using paired end 2 × 300 bp reads and a MiSeq v3
reagent kit with 5% PhiX as spike-in.
Samples
There were in total 163 fecal samples. Of these, 86 were classified
as control samples and included samples from infants never
receiving antibiotics and antibiotic-naive samples from infants
later receiving antibiotics. Only a single infant in the cohort
received a cephalosporin course, so the samples taken after
cephalosporin were omitted from the analyses. The samples of the
amoxicillin and macrolide groups are shown in Supplementary Fig.
S1 and were further divided into groups based on the duration of
time since the most recent antibiotic course began (Table 1). There
were no samples taken from macrolide-treated infants during the
first week, so early comparisons only include amoxicillin-treated
infants.
Ethics approval and consent to participate
The study was approved by the ethical committee of The Hospital
District of Helsinki and Uusimaa. The guardians of the participants
signed an informed consent.
Statistical methods
The comparisons were adjusted for infant age, birth mode, and
diet (exclusive breastfeeding, partial breastfeeding, exclusive
formula feeding, or solid feeding).
Sequence read processing and statistical analysis was con-
ducted using the R package mare,23 which uses usearch24 for
sequence processing, and the R packages vegan,25 MASS,26
nlme,27 and gstat28 for data analysis. The statistical test was
individually adapted to each bacterial taxon to make sure the data
fulfill the assumptions of the test. The specific statistical test used
for each taxon is presented in Supplementary Tables S2 and S3.
Microbiota diversity was calculated as the inverse Simpson index
and richness was calculated as the number of operational
taxonomical units (OTUs). Microbiota maturity index was calcu-
lated based on the bacterial taxa that were significantly associated
with age in the control infants. A generalized linear model with
the negative binomial distribution was used to model age
(months) as a function of the microbiota composition at the
family level in the control samples. First, the associations of all
family-level taxa were assessed and the taxa that were signifi-
cantly associated with age (p < 0.01) were selected and combined
into a single model. The full model was then reduced using Akaike
Information Criterion to obtain the final model:
Maturity= 2.721− 3.560 × Verrucomicrobiaceae+ 2.653 × Rumi-
nococcaceae+ 27.760 × Peptostreptococcaceae+ 1.754 × Lachnos-
piraceae− 22.642 × Carnobacteriaceae− 2.088 ×
Porphyromonadaceae.
Table 1. Number of samples per time group and amoxicillin and macrolide groupsa.
Days since the beginning of course 0 1 2–3 4 5–8 12–40 46–115 >169
Amoxicillin (no. of infants= 20; total number of samples= 66) 5 5 7 7 8 12 12 10
Macrolide (no. of infants= 4; total number of samples= 10) 0 0 0 0 0 6 3 1
aFor comparisons in each time group, all control samples were used (N= 86 samples prior to any antibiotic from 22 infants). A single sample after
cephalosporin therapy not included.
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RESULTS
We recruited antibiotic-naive infants (n= 40) and the effects of
antibiotics on their gut microbiota. The infants were admitted
because of RSV infections, and during follow-up, 22 received
antibiotics (mostly because of otitis media), the introduction, dose,
and duration of the therapy prescribed at clinicians’ discretion.
Most infants received amoxicillin. Macrolide was the second most
frequently used antibiotic drug. In total, there were 163 fecal
samples for analyses from patients (median age 2.3 months at
baseline; median 4.5 samples per patient; details in Supplemen-
tary Table S1 and Supplementary Fig. S1). The microbiota
composition in the samples was characterized by variation in
the abundance of bifidobacteria, enterobacteria, and clostridia
(Fig. 1 and Supplementary Fig. S2 showing individual variation).
Samples taken before antibiotic courses clustered in the high-
bifidobacteria end of the principal coordinates plot (Fig. 1).
Samples taken at the beginning of the antibiotic course (available
in the amoxicillin group only) were characterized by high
abundance of enterobacteria. Recovery from the antibiotics was
not associated with a return of the microbiota to the original
Bifidobacterium-dominated composition but rather with an
increase in clostridia. This pattern was evident in both the
amoxicillin- and the macrolide-treated infants.
Infants treated with amoxicillin had initially, before the
beginning of the course, increased relative abundances of
Bacteroidaceae (mainly Bacteroides, p= 0.0001) Bifidobacterium
(p < 0.0001), Enterococcus (p < 0.0001), Bacillus (p= 0.014), and
Haemophilus (p= 0.003) compared to the group not introduced to
antibiotics (Supplementary Table S2). After the onset of the
amoxicillin treatment, the disruption of the microbiota composi-
tion was rapid, evident already on the first day (Fig. 2), when the
relative abundance of bifidobacteria was reduced by 50%. By day
4, bifidobacteria were nearly completely depleted, to 1.4% of the
abundance in control samples (p < 0.0001) and replaced by
enterobacteria as the dominant group (6-fold increase in
enterobacteria, p= 0.0008, Supplementary Table S3). The single
child with samples after introduction of amoxicillin–clavulanic acid
showed a somewhat different pattern but rapid recovery already
on day 6 (Supplementary Fig. S2). In addition to the change in the
dominant bacteria, the relative abundances of several other taxa
changed (Fig. 3): amoxicillin treatment resulted in a rapid, long-
term decline in enterococci (p < 0.0001), as well as temporary
declines in Bacteroidaceae (42-fold decrease, p < 0.0001) Clostri-
diaceae (37-fold decrease, p= 0.0003), Coriobacteriaceae (77-fold
decrease, p < 0.0001), Streptococcaceae (3.8-fold decrease, p=
0.02), and Veillonellaceae (37-fold decrease, p= 0.02). The findings
were not related to probiotic use (data not shown).
After the amoxicillin course ended (by days 5–8, mean duration
5 days), bifidobacteria began to recover, but even after 6 months
their relative abundance was 50% lower than that in the control
samples (p= 0.03, Figs 2 and 3, Supplementary Table S2). During
the recovery, enterobacteria were replaced by Firmicutes (2-fold
increase, p= 0.015, mostly the families Veillonellaceae, Rumino-
coccaceae, Lachnospiraceae, and Clostridiaceae, Fig. 2). After
approximately 1 month from the amoxicillin treatment, the
abundance of Coprococcus (Lachnospiraceae) was 10-fold
increased (p= 0.02), Dialister (Veillonellaceae) was 20-fold
increased (p= 0.01), and Megasphaera was 100-fold increased
(p= 0.0006), compared to controls. After ca. 6 months, the total
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abundance of Firmicutes was still 2.5-fold increased (p= 0.03),
Coprococcus was 21-fold increased (p= 0.007), and Dialister was
43-fold increased (p= 0.01).
In the macrolide-treated infants, after 1 month (the first
available samples), the relative abundance of bifidobacteria was
still 59-fold lower than that in the control samples (p= 0.004,
Supplementary Table S3), Subdoligranulum (Ruminococcaceae) was
26-fold increased (p= 0.007), and Salmonella was 45-fold
increased (p < 0.0001). After ca. 3 months, Bacillales were 20-fold
increased (p= 0.004), and Alphaproteobacteria were 25-fold
increased (p= 0.03).
As indicators of overall microbiota development, we calculated
microbial diversity (inverse Simpson index), maturity (based on a
model of age-associated bacterial taxa), and richness (number of
OTUs). Diversity initially declined during the amoxicillin course
(Fig. 4, p= 0.009) but recovered rapidly and exceeded the
expected values by 6 months post-antibiotic (p= 0.018). Micro-
biota maturity was not affected immediately by the amoxicillin
course but increased during the recovery period, reaching a
significantly higher level than in the controls at 1 month after the
course (p= 0.004). The increase in microbiota maturity was
particularly dramatic in the macrolide-treated infants (p= 0.001).
Microbiota richness declined rapidly during the first day of
amoxicillin treatment (p= 0.01), which was associated with a loss
of 20 OTUs on average (30% of the original 60 OTUs). After the
cessation of the antibiotic, the microbial richness recovered
quickly.
The temporal development of the microbiota composition in
infants given amoxicillin and in infants not given any antibiotic is
shown in Supplementary Figs S3 and S4, respectively.
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DISCUSSION
Analyzing the temporal dynamics of the infant gut microbiota
before, during, and after antibiotic treatment, we have shown that
a single course of amoxicillin, the most commonly used antibiotic
in the pediatric population, results in the long-term disruption of
the gut microbiota composition in infants. Rather than returning
to the original composition after the course, the microbiota begins
an accelerated maturation toward low abundance of bifidobac-
teria and increased abundance of clostridia. Hence, amoxicillin
does not just temporarily affect the relative abundance of
dominant bacteria sensitive to this drug29 but appear to
profoundly alter the ecology of the early microbiota succession
in the developing infant.
The observed changes are unlikely to be caused by the infection
for which the antibiotic was prescribed, since the changes
occurred after the beginning of the antibiotic course and showed
a clear temporal pattern matching with the onset and end of the
antibiotic treatments. Furthermore, all children in our cohort,
including the controls, had an RSV infection.
The initial response of the infant gut microbiota to amoxicillin
was rapid and dramatic. Many significant changes occurred
already on the first day, and by day 4, the microbiota composition
was completely changed. Since each successive day of treatment
was associated with further exacerbation of the alterations, it is
clear that minimizing the duration of the course would help to
reduce the damage on the microbiota. The most dramatic
immediate effect of the amoxicillin treatment was the replace-
ment of bifidobacteria with enterobacteria. Although the abun-
dance of enterobacteria quickly returned to normal levels after the
antibiotic course, the overall microbiota composition did not
return to the original state.
In healthy, breastfed infants, bifidobacteria form the dominant
taxon, beginning to slowly decline after weaning, being replaced
by adult-type clostridia.1 The time window for Bifidobacterium
dominance is thus normally between the first and the sixth month
of age. At the time of the antibiotic treatments, the infants in our
cohort were on average almost 4 months old. Our results show
that antibiotic treatments during this age period cause a severe
depletion of bifidobacteria that continues at least for 6 months,
i.e., past the time window for Bifidobacterium dominance. In other
words, antibiotics during this age period end the Bifidobacterium
phase abruptly and prematurely.
We have previously shown that macrolide, but not amoxicillin,
treatments have a long-term detrimental impact on the relative
abundance of bifidobacteria in 2–7-year-old children, recovery
taking at least 2 years.30 In this older age group, amoxicillin had
modest effects on the microbiota compared to macrolides and
appeared as a safer alternative. The current results indicate that
the infant microbiota may be more fragile than that of older
children to the effects of antibiotics, since both amoxicillin and
macrolide antibiotics had similar, very strong effects. Therefore,
amoxicillin cannot be considered a microbiota-friendly antibiotic
in young infants. The difference could also be due to different
sampling time frame: in the previous study, the samples were
taken several months and even years after the antibiotic course.
The pattern of low bifidobacterial and high clostridial abun-
dance in infants has previously been linked with increased risk of
allergic diseases in later life.31 Bifidobacteria can modulate several
immunological pathways on both innate and adaptive immunity,
promoting mucosal and systemic immune homeostasis.32 They
also make pili that interact with the gut epithelium and stimulate
proliferation.33,34
These results suggest that antibiotic treatment, which causes a
replacement of bifidobacterial first with lipopolysaccharide-
producing enterobacteria and then with clostridia, whose
immunological effects are very different from those of bifidobac-
teria, likely results in increased inflammatory responsiveness of the
host. Interestingly, pediatric patients with inflammatory bowel
disease often have an increased abundance of enterobacteria35,36
or decreased abundance of bifidobacterial,37 and we recently
found that the abundance of bifidobacteria predicts positive
treatment response in these patients.36
Intestinal microbiota is a key source of microbial signals that are
required to the balanced postnatal development of innate and
adaptive immune systems.38,39 The extent and duration of early
microbiota perturbations that may lead to deviated physiological
state in humans is unclear. However, the accumulating evidence
of negative long-term health consequences of early antibiotic
treatments indicate that the early disruption of normal gut
microbiota development may be detrimental to host health.
Intriguingly, we have recently shown that supplementation with
bifidobacteria is able to reduce the impact of antibiotics on the
infant gut microbiota.40 Thus further studies are needed to study
whether specific bifidobacterial strains given during and after
antibiotic treatments in infants are able to restore the microbiota
to age-dependent maturational stage.
As a limitation, the number of available samples, however, was
low, like in most pediatric studies, and especially in the control
group, there were few long-term samples. Also, the data available
did not allow any conclusions related to the dosing of antibiotics.
CONCLUSIONS
A single course of common antibiotics resulted in aberration of
infant microbiota lasting for several months. Antibiotic use may
result in increased inflammatory responsiveness of the host as
suggested by the replacement of bifidobacteria with clostridia and
enterobacteria. As antibiotic use in infants modifies especially
bifidobacterial levels, further studies are warranted whether
administration of bifidobacteria will provide health benefits by
normalizing the microbiota during antibiotic courses.
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